Baylor University (BU)

Competition and moral behavior: A meta-analysis of forty-five crowd-sourced experimental designs (2023) Huber C, Dreber A, Huber J, Johannesson M, Kirchler M, Weitzel U, Abellán M, et al. Journal article Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) Rugo HSS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SMM, Cardoso F, Bardia A, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022) Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al. Conference contribution Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction (2022) Sugano K, Spechler SJ, El-Omar EM, Mccoll KEL, Takubo K, Gotoda T, Fujishiro M, et al. Journal article, Review article Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al. Journal article Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States (2022) Fasching P, Huang M, Haiderali A, Xue W, Pan W, Zhou ZY, Hu P, et al. Conference contribution Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1 (2022) Fasching P, Huang M, Haiderali A, Pan W, Hu P, Chaudhuri M, De Tilleghem CLB, et al. Conference contribution Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (2022) Huang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching P, O'Shaughnessy J Journal article, Review article